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Introduction 
Group B Streptococcus (GBS) infection in pregnancy can increase the risk of neonatal 
infection from mother to baby during labour. This can cause early and late onset 
sepsis in newborns, maternal infection, stillbirth, and may contribute to preterm birth 
(Lawn et al 2017). In 2014-2015, the incidence of early-onset GBS in the UK and 
Ireland within the first six days of life was 0.57/1000 births (517 cases) (O’Sullivan et 
al 2019). Of these births, 5.2 per cent died (27 cases). Current guidelines recommend 
that intrapartum antibiotic prophylaxis (IAP) should be offered to women who have 
been identified as having GBS infection during their current pregnancy (Hughes et al 
2017). However, treating all women with the infection increases exposure to adverse 
effects from the antibiotics (adverse reactions, antibiotic resistance). A Cochrane 
Review assessed the impact of administering IAP during labour for maternal GBS on 
mortality from any cause, GBS infection and infections other than GBS (Ohlsson and 
Shah 2009).  The review was updated in 2014 (Ohlsson and Shah 2014). 
 
The review 
The review authors searched the Cochrane Pregnancy and Childbirth Group’s Trials 
Register for randomised controlled trials (RCTs) that assessed the impact of IAP on 
neonatal GBS infections. The updated review (Ohlsson and Shah 2014) did not 
identify any new trials, so the results remain unchanged from the original review. 
Trials that were included in the review administered IAP to mothers known to be GBS-
positive at any time during the pregnancy. The comparison groups were mothers who 
received no treatment, a placebo treatment or a different type of antibiotic. The 
primary outcomes of interest were neonatal mortality by any cause, neonatal mortality 
from early onset GBS infection (within seven days of birth) or from infections caused 
by bacteria other than GBS. Secondary outcomes included early GBS infection, late 
onset GBS sepsis (>7 days) and maternal outcomes, including postpartum infection 
and sepsis. 
 
What they found 
The review included data from 852 women in four trials. Three of these trials 
(including 500 women) evaluated the effectiveness of IAP against receiving no 
treatment. One trial compared the effects of ampicillin versus penicillin.  
The authors found that there was no significant effect of IAP on neonatal mortality 
from any cause (including GBS or from other bacterial infections). There was, 
however, a significant reduction in the incidence of early GBS infection in neonates. 
The authors estimated that, in order to see any benefit in one case, 25 women would 
need to be treated with IAP. There was also a significant reduction in the incidence of 
probable early GBS infection in neonates following IAP. There were no significant 
differences in the incidence of late onset GBS infection or infection due to other 
causes in neonates. Maternal outcomes including sepsis or postpartum infection 
indicated no significant differences. One trial (including 352 women) assessed the 
use of ampicillin versus penicillin and found no significant difference in outcome for 
mother or baby. 
 
Quality of the evidence 
All identified studies were assessed by two authors for inclusion in the review and 
were subsequently assessed using the Cochrane risk-of-bias tool. Authors assessed 
the likelihood and level of bias and whether it was likely to impact on the findings. 
Overall, the quality of the included studies was found to be poor and the risk of bias 
was ‘high’ for one or more key domains in how the studies were conducted. This 
seriously weakens confidence in the interpretation of the results. The authors also 
raised concerns regarding the completeness and applicability of the evidence. These 
include a lack of pre-set sample sizes and a lack of placebo treatments within the 
control groups. They also note that the women and care-providers within the studies 
were aware of the group assignment. 
 
Implications for midwifery practice 
The administration of intrapartum antibiotics for known maternal Group B 
Streptococcus appears to reduce the occurrence of early GBS infection in the neonate, 
when compared to no treatment. There are no clear differences demonstrated for 
neonate deaths, late onset GBS infection or maternal outcomes, including sepsis. Due 
to the high risk of bias identified in the three studies investigating IAP, the authors are 
unable to make any recommendations to inform practice. They also state that 
information is lacking on whether intrapartum ampicillin is preferable to penicillin for 
women with GBS infection. 
 
Conclusions 
Administering antibiotics during the intrapartum period appears to reduce the early 
onset of GBS infection. However, the authors exercise caution with these results, as 
they found a high risk of bias in the study methodology and execution. They conclude 
that there is insufficient evidence from well-conducted trials, to recommend IAP for 
reducing early onset GBS disease in neonates. 
 
The authors also comment that, given the common practice of administering IAP to 
women with GBS, it has been poorly studied. The implication for research is that future 
studies should be both well-designed and conducted. TPM 
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